|Videos|March 29, 2018

Retinal Signs and Cognitive Decline Over 20 Years

A study looked at changes in retinal signs with fundus photography and their association with cognitive decline.

A study looked at changes in retinal signs with fundus photography and their association with cognitive decline, as measured by a composite score of neuropsychological tests over 20 years.¹

The bottom line

Loss of retinal vascular integrity (ie, moderate and severe retinopathy and its components) was associated with a greater 20-year decline in cognitive function compared with no retinopathy. Differences were similar regardless of race or presence or absence of diabetes. The eye is not only the window to the soul, but also it may be an indicator of relevant cognitive decline.

Reference

1. Deal JA, Sharrett AR, Rawlings AM, et al. Retinal signs and 20-year cognitive decline in the Atherosclerosis Risk in Communities Study. Neurology. 2018;90:e1158-e1166.

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Subscribe Now!

Retinal Signs and Cognitive Decline Over 20 Years

Newsletter

Related Content

New Guidelines Aim to Redefine Penetrating Brain Injury Care

Efgartigimod Effective in Seronegative gMG, Obexelimab Meets Primary End Point, FDA Accepts NDA for Tau Tracer MK-6240

Episode 153: Overviewing the 2025 Alzheimer’s Association’s Blood-Based Biomarker Guidelines

FDA Accepts New Drug Application for Tau PET Imaging Agent MK-6240 in Alzheimer Disease

Benzodiazepines and Antipsychotics Tied to Higher Mortality in Hospice Patients With Dementia

Latest CME

Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice

Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment

Patient, Provider, and Caregiver Connection™: Pediatric Myasthenia Gravis—Current Treatment and Emerging Concepts

Mind Moments™: Optimizing Management for Patients with Generalized Myasthenia Gravis

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Cases and Conversations™: Navigating the Complexities of Managing Myasthenia Gravis in Pediatric and Pregnant Patient Populations

Identifying and Treating CIDP in the Modern Era

Cases and Conversations™: Little Voices, Big Challenges – Comprehensive Care for Pediatric Spinal Muscular Atrophy

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Patient, Provider, and Caregiver Connection: Improving Diagnosis and Care for Adolescent Myasthenia Gravis Patients – A New Frontier

A New Era in NMOSD Treatment: Optimizing Therapeutic Transitions and Reducing Patient Burden

PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS)

PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)

PER Postgame™: Updates from ANNA in the Management of IgA Nephropathy

Patient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Identifying and Treating Generalized Myasthenia Gravis in the Modern Era

Addressing Unmet Needs for Patients With Spinal Muscular Atrophy—Understanding Patient Challenges and Management Approaches

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

FDA Issues Complete Response Letter for Spinocerebellar Ataxia Agent Troriluzole

Dental Caries and Periodontal Disease Increase Ischemic Stroke Risk, Study Shows

Understanding the Global Impact of the Honolulu Asian Aging Study: George W. Ross, MD

FDA Feedback Provides Clarity for Phase 3 Trial of Neflamapimod in Dementia With Lewy Bodies

Acute Stroke Therapy LT3001 Eyes Phase 3 Studies Following Positive Phase 2b Data